Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Tumor Progression
CUI: C0178874
Disease: Tumor Progression
0.040 GeneticVariation BEFREE The EGFR resistance mutation T790M should be monitored at cancer progression. 31445213 2019
Tumor Progression
CUI: C0178874
Disease: Tumor Progression
0.040 GeneticVariation BEFREE Liquid biopsies (LB) are used routinely in clinical practice in two situations for late stage non-small-cell lung cancer (NSCLC) patients, (i) at the initial diagnosis when looking for activating mutations in EGFR in the absence of analyzable tissue DNA and, (ii) during tumor progression on a tyrosine kinase inhibitor treatment to look for the resistance mutation T790M in EGFR. 29069959 2017
Tumor Progression
CUI: C0178874
Disease: Tumor Progression
0.040 GeneticVariation BEFREE Finally, in the prospective series, SiRe detected 8.7% (4/46) of EGFR mutations at baseline and 42.9% (9/21) of EGFR p.T790M in patients at tumour progression. 28170370 2017
Tumor Progression
CUI: C0178874
Disease: Tumor Progression
0.040 GeneticVariation BEFREE Detection of T790M with plasma DNA was correlated with EGFR mutation type, exon 19 deletions and tumor progression. 26577492 2016